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A number of reagents that prevent thrombosis have been developed but were found to have serious side effects. Therefore, we
sought to identify complementary and alternative medicinal materials that are safe and have long-term efficacy. In the present
studies, we have assessed the ability of chlorine e6 (CE6) to inhibit ADP-induced aggregation of rat platelets and elucidated the
underlying mechanism. CE6 inhibited platelet aggregation induced by 10𝜇M ADP in a concentration-dependent manner and
decreasedintracellularcalciummobilizationandgranulesecretion(i.e.,ATPandserotoninrelease).Westernblottingrevealedthat
CE6stronglyinhibitedthephosphorylationsofPI3K,Akt,c-JunN-terminalkinase(JNK),anddifferentmitogen-activated protein
kinases (MAPKs) including extracellular signal-regulated kinase 1/2 (ERK1/2) as well as p38-MAPK. Our study also demonstrated
that CE6 significantly elevated intracellular cAMP levels and decreased thromboxane A2 formation in a concentration-dependent
manner. Furthermore, we determined that CE6 initiated the activation of PKA, an effector of cAMP. Taken together, our findings
indicatethatCE6mayinhibitADP-inducedplateletactivationbyelevatingcAMPlevelsandsuppressingPI3K/Aktactivity.Finally,
these results suggest that CE6 could be developed as therapeutic agent that helps prevent thrombosis and ischemia.
1. Introduction
Vascularstructureintegrityisessentialforthemaintenanceof
cardiovascularfunction.Exposuretoaninjuredvascularwall
triggers the activation of platelets to promote the recovery of
blood vessel integrity. However, aberrant platelet activation
may result in thrombosis that could lead to the development
of serious vascular diseases such as cerebral stroke and
myocardial infarction.
Platelet agonists (e.g., ADP, thrombin, thromboxane A2
(TXA2), and epinephrine) activate platelets via G protein-
coupled receptor (GPCR) pathways [1, 2], and the activa-
tions of distinct G proteins are integrated by interacting
downstream molecules [3, 4]. Thus, once a specific GPCR is
activatedbyanagonist,otherGPCRsareeventuallyactivated
byrecruitedGPCRligandsandformapositivefeedbackloop
which greatly amplifies activation signals [1, 5]. ADP and
TXA2, two factors secreted during platelet activation, serve
as both mediators and agonists. On the other hand, cyclic
adenosinemonophosphate(cAMP)andnitricoxide(NO),an
endogenous gaseous molecule, have the opposite effects on
platelet activation [2, 6, 7]. Adenylyl cyclase (AC) catalyzes
the conversion of 5
򸀠-ATP into cAMP whereas phosphodi-
esterase (PDE) hydrolyzes cAMP. Intracellular cAMP levels
are thus tightly regulated by AC and PDE [8].2 Evidence-Based Complementary and Alternative Medicine
An u m b e ro fe v e n t si n v o l v e di np l a t e l e ta c t i v a t i o na r e
largely dependent on intracellular calcium levels ([Ca
2+]𝑖)
[9], and elevation of [Ca
2+]𝑖 is considered to be a prerequisite
for platelet aggregation. The final common event of platelet
aggregationisthebindingoffibrinogentointegrin𝗼IIb𝗽3.The
activation of integrin 𝗼IIb𝗽3 mediates outside-in signaling
that stimulates tyrosine phosphorylations to complete the
processofplateletaggregation[10]. As such, platelet agonists,
such as ADP and collagen, increase the affinity of 𝗼IIb𝗽3 for
fibrinogen that forms crosslinks between platelets [11].
Platelet activation triggers hemostasis, and the aberrant
activation of platelets leads to thrombotic complications [12,
13]. Thrombosis is the formation of blood clots that can
obstruct blood flow in a vessel. When thrombi form in
a vessel, tissues can become hypoxic. This might lead to
the development of serious thrombotic diseases including
cerebral stroke and myocardial infarction [14, 15].
Over the last couple of decades, a number of antiplatelets
drugs have been developed in response to the growing
concern about cardiovascular diseases. However, these drugs
were found to have undesirable side effects resulting from
the direct inhibition of clotting factors. In our effort to find
complementary and alternative compounds, we discovered
CE6, a natural product that is made by chlorella species
[16]. These algae have been used as traditional medicine in
India [17]a n dT u r k e y[ 18] for treating inflammation-related
diseases. Previous studies have also reported that CE6 has
anticancer [19] and antiviral [20]e ff e c t s .M c M a h o ne ta l .
[21] have examined the effects of CE6 on the changes of
bloodflowbymeasuringthediametersofcremasterarterioles
ex vivo. Samal’ et al. also described the antithrombotic
effects of CE6 [22], but the underlying mechanism affecting
the antiplatelet activities of this compound has not been
elucidated. Therefore, we performed the current study to
investigate the inhibitory effect of CE6 on ADP-induced
platelet aggregation and the associated signaling mechanism
governing this activity.
2. Materials and Methods
2.1. Materials. CE6 was obtained from Frontier Scientific,
Inc.(Figure 1,Logan,UT ,USA).PurityoftheCE6samplewas
morethan95%.A50mMstocksolutionofCE6wasprepared
in DMSO and stored at −20
∘Ci nt h ed a r k .Th eC E 6w a s
diluted to the appropriate concentration immediately before
all experiments were performed.
Fura-2/AM was obtained from Sigma Chemical Co. (St.
Louis, MO, USA). ADP was procured from Chrono-log
(Havertown, PA, USA). Antibodies against phospho-p44/42,
p44/42, phospho-p38, p38, phospho-SAPK/JNK, phospho-
PI3K (p85), phospho-Akt, and 𝗽-actin were acquired from
Cell Signaling (Beverly, MA, USA). Antibody against the
catalytic subunit of PKA (PKA𝗼/𝗽/𝗾 cat) was from Santa
Cruz (Delaware Avenue, CA, USA). ATP assay kits were
purchased from Biomedical Research Service Center (Buf-
falo, NY, USA). A TXB2 enzyme immunoassay (EIA) kit was
purchased from Enzo Life Sciences (Plymouth Meeting, PA,
USA).AcAMPEIAkitwasobtainedfromCaymanChemical
(AnnArbor,MI,USA).FibrinogenAlexaFluor488conjugate
O
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N
N
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Figure 1: The chemical structure of CE6.
wasobtainedfromMolecularProbes(Eugene,OR,USA).All
chemicals were of reagent grade.
2.2. Rat Platelet Preparation. Rat platelets were isolated and
prepared as previously described [23]. Male Sprague Dawley
rats 60d old and weighing from 240 to 250g were obtained
from Orient Co. (Seoul, Republic of Korea). The animals
were maintained in a standard laboratory animal facility
with free access to food and water. Whole blood from the
rats was collected using a 23G needle inserted into the
abdominal aorta, and then transferred to a 15mL test tube
containing 1mL of an acid/citrate/dextrose (ACD) solution
(85mM trisodium citrate, 83mM dextrose, and 21mM citric
acid)asananticoagulant.Thebloodwascentrifugedat170×g
for 7min to obtain platelet-rich plasma (PRP). In order to
remove residual erythrocytes, the PRP samples were again
centrifuged at 120×gf o r7m i n .T oi s o l a t et h ep l a t e l e t sa n d
remove the ACD solution, the PRP was centrifuged twice at
350×g for 10min with a washing buffer. The concentration
of platelets from the precipitate was adjusted to 3×1 0
8/mL
with Tyrode buffer (137mM NaCl, 12mM NaHCO3,5 . 5m M
glucose, 2mM KCl, 1mM MgCl2,a n d0 . 3 m MN a H P O 4,
pH7.4) for the aggregation assay. Platelet preparation was
conducted at room temperature. Experimental procedures
andprotocolsinvolvinganimalswerereviewedandapproved
by the Ethics Committee of the College of Veterinary
Medicine, Kyungpook National University (Daegu, Republic
of Korea).
2.3. PlateletAggregationAssay. Plateletaggregationwaseval-
uated as previously described [24]. Aggregation was moni-
tored by measuring light transmission with an aggregometer
(Chrono-log, Havertown, PA, USA). The washed platelets
(3×10
8/mL) were preincubated at 37
∘C for 2min with either
C E 6o rv e h i c l ea n dt h e ns t i m u l a t e dw i t h1 0 𝜇MA D P .Th e
mixture was further incubated for 5min with stirring. The
vehicle concentration was less than 0.1% to minimize the
effect of this reagent.
2.4.[Ca
2+]𝑖 Measurement. Theintracellularcalciumioncon-
centration ([Ca
2+]𝑖) was measured with Fura-2/AM asEvidence-Based Complementary and Alternative Medicine 3
previouslydescribed[25].Briefly,theplateletswereincubated
with 5𝜇M of Fura-2/AM for 30min at 37
∘Ca n dw a s h e d .Th e
Fura-2-loadedplatelets(3×10
8/mL)werethenpre-incubated
with CE6 for 2min at 37
∘C in the presence of 1mM CaCl2,
andsubsequentlystimulatedwithADPfor5min.Fluorescent
signals were recorded using a Hitachi F-2500 fluorescence
spectrofluorometer (F-2500, Hitachi, Japan). Light emission
was measured at 510nm, with simultaneous excitation at 340
and 380nm that changed every 0.5s. Fura-2 fluorescence
in the cytosol measured with the spectrofluorometer was
calculated as previously described by Schaeffer and Blaustein
[26]w i t ht h ef o l l o w i n gf o r m u l a :[Ca
2+]𝑖 224nM ×( 𝐹−
𝐹min)/(𝐹max−𝐹),inwhich224nMisthedissociationconstant
of the Fura-2-Ca
2+ complex, and 𝐹min and 𝐹max represent
the fluorescence intensity levels at very low and very high
Ca
2+ concentrations, respectively. In our experiment, 𝐹max
was the intensity of the Fura-2-Ca
2+ complex fluorescence
at 510nm after the platelet suspension containing 1mM of
CaCl2 had been solubilized with Triton X-100 (0.1%). 𝐹min
was the fluorescence intensity of the Fura-2-Ca
2+ complex
at 510nm, after the platelet suspension containing 20mM
Tris/3mM of EGTA had been solubilized with Triton X-
100 (0.1%). 𝐹 represented the intensity of Fura-2 complex
fluorescenceat510nmaftertheplateletsuspensionwhichwas
s t i m u l a t e dw i t hA D Pw i t ho rw i t h o u tC E 6i nt h ep r e s e n c eo f
1mM CaCl2.
2.5. ATP Release Assay. Washed platelets (3×1 0
8/mL) were
pre-incubated for 2min at 37
∘Cw i t hv a r i o u sc o n c e n t r a t i o n s
of CE6 and then stimulated with 10𝜇M ADP. After the reac-
tionwasterminated,thecellswerecentrifugedandthesuper-
n a t a n t sw e r eu s e df o rt h ea s s a y .A T Pr e l e a s ew a sm e a s u r e d
in a luminometer (GloMax 20/20, Promega, Madison, USA)
using an ATP assay kit (Biomedical Research Service Center,
Buffalo, NY, USA) according to manufacturer’s instructions.
2.6. Serotonin Release Assay. A platelet aggregation assay
was carried out as described previously. After terminat-
ing the aggregation reaction, the mixture was immediately
centrifuged at 12,000×gf o r5 m i na t4
∘C. The supernatant
was collected and serotonin release was measured with a
serotonin ELISA kit (Labor Diagnostika Nord GmbH &
Co, Nordhorn, Germany) according to the manufacturer’s
instructions.
2.7. Cyclooxygenase-1 (COX-1) Activity Assay. The washed
platelets (3×1 0
8/mL) with 1% protease inhibitor cocktail
(Sigma Chemical Co., St. Louis, MO, USA) were sonicated
10 times at sensitivity 100% for 20s on ice with a model
HD2070sonicator(BandelinElectronic,Bandelin,Germany)
to obtain platelet lysates. The homogenates were centrifuged
at 12,000×gf o r1 5 m i na t4
∘Ct or e m o v ec e l ld e b r i s .Th e
supernatant was used to measure COX-1 activity. The platelet
lysates were pre-incubated with 330nM SC-560, a selective
COX-1 inhibitor, and with or without various concentrations
of CE6 at 37
∘Cf o r3 0 m i n .C O X - 1a c t i v i t yo ft h et r e a t e d
platelet lysates was then measured with a COX-1 fluorescent
assay kit (Cayman Chemical Co., Ann Arbor, MI, USA)
according to the manufacturer’s protocol.
2.8. Measurement of Thromboxane A Synthase (TXAS) Activ-
ity. The washed platelets (3×1 0
8/mL) with 1% protease
inhibitor cocktail (Sigma Chemical Co., St. Louis, MO, USA)
weresonicated10timesatsensitivity100%for20sonicewith
a model HD2070 sonicator (Bandelin Electronic, Bandelin,
Germany) to obtain platelet lysates. Next, the homogenates
werecentrifugedat12,000×gf o r1 5m i na t4
∘Ct or e m o v ec e l l
d e b r i s .TXA Sa c t i v i t yo ft h es u p e r n a t a n tw a st h e nm e a s u r e d .
The platelet lysates were pre-incubated with 11nM ozagrel,
a TXAS inhibitor, with or without various concentrations
of CE6 at 37
∘C for 30min. The reaction was initiated by
the addition of prostaglandin H2 (PGH2) and allowed to
proceed for 1min at 37
∘C. The reaction was then terminated
by the addition of 1M citric acid. After neutralization with
1N NaOH, the concentration of thromboxane B2 (TXB2), a
stablemetaboliteofTXA2, was determined with a TXB2 EIA
kit (Cayman Chemical Co, Ann Arbor, MI, USA) according
to the manufacturer’s instructions.
2.9. Evaluation of TXB2 Generation. Washed platelets (3×
10
8/mL) were pre-incubated with or without CE6 for 2min
at 37
∘C in the presence of 1mM CaCl2,a n dt h e ns t i m u l a t e d
with 10𝜇M ADP for 5min. The reactions were terminated
byaddingice-cold2.5mMEDTAand100𝜇Min do m eth acin.
After centrifugation at 12,000×gf o r3m i na t4
∘C, the super-
natantwascollectedandtheconcentrationofTXB2 wasmea-
sured using a TXB2 EIA kit according to the manufacturer’s
protocol.
2.10. Measurement of cAMP Levels. Washed platelets (3×
10
8/mL) were incubated at 37
∘Cf o r5 m i nw i t hv e h i c l e
( D M S O ) ,C E 6( 1 ,4 ,a n d8𝜇M), or forskolin (1𝜇M) in either
t h ep r e s e n c eo ra b s e n c eo f1 0𝜇M ADP with stirring in an
aggregometer (Chronolog, Havertown, PA, USA). Imme-
diately after terminating the incubation, the mixture was
boiled for 5min and cooled to 4
∘C. The samples were then
centrifuged at 2,000×gf o r1 0m i na t4
∘C. The concentration
of cAMP in the supernatants was determined with a cAMP
EIA kit according to the manufacturer’s protocol.
2.11.Immunoblotting. Platelet suspensions(3×10
8/mL)were
pre-incubated with CE6 or vehicle (0.1% (v/v) DMSO)
at 37
∘C for 2min. Platelet activation was induced by the
addition of 10𝜇MA D Pa n dt h er e a c t i o nw a sa l l o w e dt o
proceed for 5min. After terminating the reaction, lysates
were then prepared by solubilizing and centrifuging the
platelets in sample buffer (0.125M Tris-HCl, pH6.8; 2%
SDS,2%𝗽-mercaptoethanol,20%glycerol,0.02%bromophe-
nol blue, 1𝜇g/mL phenylmethylsulfonyl fluoride (PMSF),
2𝜇g/mLaprotinin,1𝜇g/mLleupeptin,and1𝜇g/mLpepstatin
A). Protein concentration was determined using a BCA
assay (Pro-Measure; iNtRON Biotechnology, Seoul, Repub-
lic of Korea). Total cell proteins (30𝜇g) from the platelet
lysate were resolved by 10% SDS-PAGE and transferred to
nitrocellulose membranes in transfer buffer (25mM Tris,4 Evidence-Based Complementary and Alternative Medicine
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Figure2:TheinhibitoryeffectofCE6onplateletaggregationinducedbyADP.Platelets(3×10
8/mL)werepreincubatedwithorwithoutCE6
(1.63–30M) in the presence of 1mM CaCl2 for 2min at 37
∘C. The platelet aggregation was then induced by 10𝜇MA D Pa n dm e a s u r e dw i t h
a turbidimetric aggregometer. The aggregation reaction was terminated after 5min, and the percent aggregation rate was calculated. Each
graph shows the mean ± SEM of four independent experiments.
∗𝑃 < 0.05,
∗∗𝑃 < 0.01,a n d
∗∗∗𝑃 < 0.001 compared to the agonist control.
pH8.5; 0.2M glycine; and 20% methanol). The membranes
w e r eb l o c k e di nT B S - Tc o n t a i n i n g5 %n o n f a td r ym i l k
and incubated with primary antibody diluted in a blocking
solution. The blots were then incubated with horseradish
peroxidase-conjugated secondary antibody. Antibody bind-
ing was visualized using enhanced chemiluminescence
(iNtRON Biotechnology, Seoul, Republic of Korea).
2.12. Assessment of Fibrinogen Binding to Integrin 𝗼IIb𝗽3.
Fibrinogen Alexa Fluor 488 conjugate binding to washed
platelets was quantified by flow cytometry. Briefly, washed
platelets (3×1 0
8/mL) were pre-incubated for 2min with
various concentrations of CE6 at room temperature in the
presenceof0.1mMCaCl2.Theplateletswerethenstimulated
with ADP for 5min, immediately incubated thereafter with
fibrinogen Alexa Fluor 488 (20𝜇g/mL) for 5min, and finally
fixed with 0.5% paraformaldehyde at 4
∘Cf o r3 0 m i n .Th e
platelets were pelleted by centrifugation at 2,000×ga t4
∘C
and resuspended in 500𝜇L PBS. Since the activation of
integrin 𝗼IIb𝗽3 is largely dependent on the generation of
Ca
2+,nonspecificbindingoffibrinogentointegrin𝗼IIb𝗽3 was
measured by assessing fibrinogen binding in the presence
of the calcium chelator EGTA (1mM). The fluorescence of
each platelet sample was analyzed using a FACS Calibur
cytometer (BD Biosciences, San Jose, CA, USA), and data
were analyzed using CellQuest software (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA).
2.13. Statistical Analysis. Data were analyzed with a one-way
analysis of variance followed by a post hoc Dunnett’s test
in order to measure statistical significance of the differences
observed (SAS Institute Inc., Cary, NC, USA). All data are
presented as the mean ± standard error of the mean (SEM).
𝑃 values of 0.05 or less were considered to be statistically
significant.
3. Results
3.1. CE6 Inhibits ADP-Induced Platelet Aggregation. We
first determined whether CE6 affected platelet aggregation
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Figure 3: The inhibitory effect of CE6 on [Ca
2+]𝑖 increased by
ADP. Washed platelets (3×1 0
8/mL) were incubated with calcium
fluorophore (5M, Fura-2/AM) and stimulated with 10𝜇MA D P .
[Ca
2+]𝑖 w a st h e nm e a s u r e da sd e sc r i be di nSection 2.Th er e s u l t sa r e
presented as the mean ± SEM of three independent experiments.
∗∗𝑃 < 0.01 and
∗∗∗𝑃 < 0.005 compared to the agonist control.
###𝑃 < 0.001 compared to the basal level.
induced by 10𝜇M ADP. CE6 significantly inhibited ADP-
induced platelet aggregation in a concentration-dependent
manner with an IC50 of 12.53 ± 2.79𝜇M( Figure 2).
3.2. CE6 Prevents ADP-Induced [Ca
2+]𝑖 Elevation. Since the
mobilizationofcalciumisacrucialstepforplateletactivation
anddegranulation[27],weexaminedtheeffectofCE6onthe
elevation of [Ca
2+]𝑖 induced by ADP. As shown in Figure 3,
ADP(10𝜇M)increased[Ca
2+]𝑖 to750nM.Thiswasmarkedly
suppressed by CE6 in a concentration-dependent manner.
Our results suggest that the inhibition of platelet aggregation
by CE6 is potentially mediated by the regulation of [Ca
2+]𝑖.
3.3. CE6 Inhibits ATP Release from ADP-Activated Platelets.
Since the contents of dense granules are rapidly released
as an early event of platelet activation [28], we measured
ATP secretion induced by ADP as an index of dense granuleEvidence-Based Complementary and Alternative Medicine 5
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Figure4:EffectsofCE6ongranulesecretionfromtheADP-activatedplatelets.Washedplatelets(3×10
8/mL)werepre-incubatedwithCE6at
the indicated concentrations and stirred in an aggregometer for 2min prior to stimulation with ADP for 5min. The reaction was terminated,
and an ATP release assay (a) and serotonin release assay (b) were performed. Bar graphs show the mean ± SEM of at least four independent
experiments.
∗∗𝑃 < 0.01 and
∗∗∗𝑃 < 0.001 compared to the agonist control.
###𝑃 < 0.001 compared to the basal level.
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Figure5:EffectofCE6onADP-inducedTXB2 generation.Platelets
(3×10
8/mL) were pre-incubated with or without CE6 (7.5–30M) in
thepresenceof1mMCaCl 2 for2minat37
∘C.Theplateletswerethen
stimulated with 10𝜇M ADP for 5min at 37
∘C. After terminating
the aggregation reaction, the supernatant was collected and TXB2
production was measured using a TXB2 EIA kit according to the
manufacturer’s instructions. Bar graphs show the mean ± SEM of
three independent experiments performed.
∗∗𝑃 < 0.01 and
∗∗∗𝑃<
0.005comparedtotheagonistcontrol.
###𝑃 < 0.001comparedtothe
basal level.
secretion. Compared to treatment with vehicle, CE6 signifi-
cantly inhibited ATP release from ADP-stimulated platelets
(Figure 4).
3.4.CE6ReducesSerotoninReleasefromADP-ActivatedPlate-
lets. Serotonin (5-hydroxytryptamine) accumulates in plate-
let dense granules and is released during the initial stage
of platelet activation with various ligands such as collagen,
thrombin, and ADP [29, 30]. As shown in Figure 5,C E 6
significantlysuppressedADP-inducedserotoninreleasefrom
theratplateletsinaconcentration-dependentmanner.Taken
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Figure 6: Effect of CE6 on COX-1 activity in the intact platelets.
Platelets(3×10
8/mL)withproteaseinhibitorcocktailweresonicated
10 times at sensitivity 100% for 20 s on ice with sonicator. The
homogenates were centrifuged at 12,000 × g for 15 min at 4
∘Ct o
remove cell debris. The supernatant was used to measure COX-
1 activity. The platelet lysates were pre-incubated with or without
various concentrations of CE6 at 37
∘C for 30 min. COX-1 activity
ofthetreatedplatelet lysateswasthenmeasured withaCOX-1assay
kit according to the manufacturer’s protocol. Bar graphs show the
mean ± SEM of three independent experiments.
∗∗∗𝑃 < 0.005 com-
pared to the agonist control.
together, our findings showed that CE6 markedly inhibited
degranulation during the early step of ADP-induced platelet
activation.
3.5. CE6 Suppresses TXA2 Production. TXA2,al i p i dm e d i a -
tor,isakeyelementthatamplifiesactivationsignals.Toexam-
ine the effects of CE6 on TXA2 production, we quantified6 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Effects of CE6 on intracellular cAMP concentrations. Washed platelets (3×1 0
8/mL) were stirred with vehicle (DMSO) or CE6
(at the indicated concentrations), forskolin, or IBMX in an aggregometer and stimulated with 10𝜇M ADP for 5min. cAMP levels were then
measured with an immunoassay as described in Section 2. CE6 significantly increased cAMP accumulation in a concentration-dependent
manner (a). Co-incubation with CE6 and forskolin but not IBMX synergistically increased cAMP levels (b). The results are presented as the
mean±SEMofatleastthreeindependentexperiments.
∗∗𝑃 < 0.01,and
∗∗∗𝑃 < 0.005comparedtothenegativecontrol.
#𝑃 < 0.05,
##𝑃 < 0.01,
and
###𝑃 < 0.001 compared to the ADP-activated control. NS: not significant.
thelevelsofTXB2,astablemetaboliteofTXA2 inCE6-treated
platelets. As presented in Figure 6,A D Pg r e a t l yi n c r e a s e d
TXB2 generation five times more compared to the basal
level. Production of this metabolite was gradually reduced
by CE6.
3.6. CE6 Inhibits COX-1 Activity but Not TXAS Activity.
TXA2, a powerful aggregating agent that acts as an autacoid,
can be produced via sequential activation of COX-1 and
TXAS. First, COX-1 catalyzes the conversion of arachidonic
acid into PGH2, which is transformed into TXA2 with the
aid of TXAS [23]. We determined whether CE6 modulated
t h ea c t i v i t i e so fC O X - 1a n dT X A Si nu n s t i m u l a t e dr a t
platelets. Surprisingly, CE6 inhibited COX-1 activity in a
concentration-dependent manner compared to SC-560, a
selective COX-1 inhibitor (Figure 6). However, CE6 did not
affect TXAS activity (data not shown).
3.7. CE6 Increases cAMP Production in Resting and ADP-
Activated Platelets. As shown in Figure 7(a),p r e i n c u b a t i o n
with CE6 significantly increased the cAMP levels in intact
platelets. At a concentration of 8𝜇M, CE6 increased cAMP
concentrations to 95% of that observed in cells treated
with forskolin. However, ADP has a little effect on cAMP
productionwhileCE6augmentedcAMPproductioninADP-
activated platelets with the similar extent in resting platelets
(Figure 7(b)).Furthermore,coincubationwithCE6and1𝜇M
forskolin, a direct AC activator, promoted the increase of
cAMP levels induced by CE6 (Figure 7(c)). However, co-
incubationwithCE6,3-isobutyl-1-methylxanthine(IBMX),a
broad-spectrum PDE inhibitor, had a little synergistic effect
on cAMP production.
3.8. CE6 Inhibits the Phosphorylation of MAPKs, PI3K,
and Akt and Increases Expression of the PKA Catalytic
Subunit. In order to elucidate the mechanism underlyingEvidence-Based Complementary and Alternative Medicine 7
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Figure8:EffectsofCE6onADP-inducedphosphorylationofMAPKs,PI3K,andAktandonexpressionofthePKAcatalyticsubunit.Washed
platelets (3×1 0
8/mL) were pre-incubated for 2min with vehicle or CE6 at the indicated concentration. The platelets were then stimulated
with 10𝜇M ADP for 5min at 37
∘C. After terminating the reactions, total cell proteins were extracted. The proteins were separated by SDS-
PAGE and transferred onto nitrocellulose membranes. The membranes were then probed with antibodies against phospho-p44/42, p44/42,
phospho-p38, p38, phospho-SAPK/JNK, and 𝗽-actin (a); and phospho-PI3K, phospho-Akt, Akt, PKA𝗼/𝗽/𝗾 catalytic subunit, and 𝗽-actin
(b). Antibody binding was visualized by chemiluminescence. All immunoblots are representative of three or four independent experiments.
the effects of CE6 on platelets, we further examined the
phosphorylation of downstream signaling molecules includ-
ing MAPKs, PI3K, and PKA. MAPKs include extracellular
signal-relatedkinase1/2(ERK1/2orp44/42),p38MAPK,and
JNK,whichareallexpressedinratplatelets.Ourimmunoblot
analysis revealed that phosphorylation of all three MAPKs
was almost completely blocked by pre-incubation with CE6
(Figure 8(a)).
It is well-established that PI3K plays crucial role in
dense granule secretion along with signaling associated with
secondarymediatorssuchasADPandTXA2 [7].Inaddition,
PI3KandAktareknowntobephosphorylatedbyGi-coupled
receptor activation [4]. We therefore determined whether
CE6 affected PI3K and Akt phosphorylation. Pre-incubation
withCE6significantlyinhibitedthephosphorylationofPI3K
and Akt in rat platelets (Figure 8(b)).8 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Effects of CE6 on fibrinogen binding to integrin 𝗼IIb𝗽3 in ADP-activated platelets. The inhibitory effects of CE6 on fibrinogen
binding to integrin 𝗼IIb𝗽3 in ADP-stimulated platelets were measured by flow cytometry (a). Washed platelets (3×1 0
8/mL) were pretreated
with vehicle (DMSO) or CE6 at concentrations ranging from 3.25𝜇Mt o3 0𝜇M. ADP (10𝜇M) was then incubated with human fibrinogen
labeled with Alexa Fluor 488 (20 𝜇g/mL) for 5min. The cells were subsequently fixed with 0.5% paraformaldehyde at 4
∘C for 30min. Graphs
showing fluorescent intensity present the data from one experiment but are representative of four independent trials. Data are expressed
as the mean fluorescence intensity (MFI) of fibrinogen-positive platelets. Each graph presents the results expressed as percent of gated (A).
∗∗𝑃 < 0.01 and
∗∗∗𝑃 < 0.005 compared to the agonist control.
Since pre-incubation with CE6 increased cAMP produc-
tion in unstimulated platelets, we next explored whether
PKA is activated by pretreatment with CE6. As shown in
Figure 9(b), CE6 significantly enhanced expression of the
PKA catalytic subunit.
3.9. CE6 Attenuates Fibrinogen Binding to Integrin 𝗼IIb𝗽3.
OneconsequenceofADP-inducedplateletactivationisacon-
formationalchangeofintegrin𝗼IIb𝗽3 [31]tha tbindstoserum
fibrinogen. Concomitant stimulation of two ADP receptors,
P2Y1 and P2Y12,c a u s e si n t e g r i n𝗼IIb𝗽3 to assume an active
conformation [32]. To determine whether CE6 affects the
activationof𝗼IIb𝗽3,washedplateletswerepre-incubatedwith
different concentrations (3.25∼30𝜇M) of CE6 and incubated
withfibrinogenboundtoAlexaFluor488.Specificbindingof
thelabeledfibrinogenwasthenmeasured.WefoundthatCE6
inhibited fibrinogen binding in a concentration-dependent
manner (Figures 9(a) and 9(b)).
4. Discussion
I nt h ep r e s e n ts t u d y ,w ee v a l u a t e dt h ei n h i b i t o r ye ff e c t s
of CE6 on platelet aggregation and elucidated downstream
pathways involved in the inhibition of ADP-induced platelet
activationbyCE6.ATPandserotoninsecretionwasinhibited
by CE6. This compound also regulated [Ca
2+]𝑖.M o r e o v e r ,
the phosphorylation of the three MAPKs, PI3K, and Akt
was inhibited, and fibrinogen binding to integrin 𝗼IIb𝗽3 was
attenuated (Figure 10).
We demonstrated that CE6 prevented ADP-induced
[Ca
2+]𝑖 elevation in a concentration-dependent manner and
significantly suppressed dense granule secretion. Upon ADP
ADP
cAMP MAPKs/Akt
PKA Granule secretion
ATP release
Serotonin release)
Activation by CE6
Inactivation by CE6
𝗽3
([Ca2+]i
𝗼IIb
Figure10:SchematicofCE6antiplateletactivityandtheunderlying
mechanism of action.
stimulation, a rapid rise in [Ca
2+]𝑖 o c c u r sd u et oP I 3 K
activation [2]. Guidetti et al. also demonstrated that the
inhibition of P2Y12 (a Gi-coupled ADP receptor) completelyEvidence-Based Complementary and Alternative Medicine 9
prevents PKC activation and suppresses pleckstrin phos-
phorylation [2]. These findings suggest that CE6 inhibits
calcium mobilization at least partially via the inhibition of
DAG-PKC activity. Increased [Ca
2+]𝑖 subsequently triggers
platelet granule secretion (i.e., and dense granules) [33].
ATP released from dense granules causes a rapid influx of
calcium by sensitizing the ionotropic receptor P2X1 [34].
On the other hand, Ca
2+ chelation abolishes ATP release,
indicating functional complementarities [35]. In addition,
released granule contents (i.e., ATP and serotonin) help
amplify platelet activation [29, 33, 36]. Taken together, our
results along with data from the literature suggest that CE6
exerts broad inhibitory effects on granule secretion such as
calcium, ATP, and serotonin, which mediated the antiplatelet
activities of CE6.
TXA2 is an unstable aggregating factor, of which pro-
duction was significantly inhibited by pre-incubation with
CE6 in ADP-activated platelets. TXA2 is an important
mediator generated by the initial activation of phospholipase
A2. Recent studies have shown that activation of the P2Y1
purinergic receptor (Gq-coupled ADP receptor) enhances
TXA2 receptor (TP receptor) activation [37], and the TP
receptor subsequently promotes ADP secretion [38]. These
findings suggest that cross-activity exists between G protein-
mediated receptors. Given that the network between ADP
and TXA2 enables the rapid formation of a haemostatic
plug, the inhibition of TXA2 generation seems to play an
important role in mediating the inhibitory effect of CE6 on
ADP-induced activation. TXA2 is produced by sequential
activation of COX-1 and TXAS from arachidonic acid, a
b y p r o d u c to fp h o s p h o l i p i db r e a k d o w n .A sp r e s e n t e di n
Figure 6, CE6 markedly suppressed COX-1 activity but not
t h a to fT X A S( d a t an o ts h o w n ) .Th i sr e s u l ts u g g e s t st h a tt h e
inhibition of TXA2 production (determined by measuring
the TXB2 metabolite levels) by CE6 is likely due to decreased
availability of PGH2, a substrate of TXAS.
MammalianplateletsexpressthreeMAPKs:ERK1/2,p38-
MAPK, and JNK. Previous studies showed that ERK has
a crucial role in TXA2 generation [11, 19]. Moreover, ERK
activationfollowingGPIbstimulationleadstointegrin𝗼IIb𝗽3
activation [19]. p38-MAPK and ERK are known to have
important roles in granule secretion and TXA2 release,
suggesting that the effects of these two factors are secondary
to the effect on granule secretion [39]. Our results indi-
cated that CE6 suppresses dense granule secretion, TXA2
formation, and 𝗼IIb𝗽3 activation (at least in part) through
inhibitionoftheERKandp38-MAPKpathways.Ontheother
hand, previous studies have presented and demonstrated
that JNK−/− platelets are associated with increased bleeding
time,decreasedintegrin𝗼IIb𝗽3 activation,andseveregranule
secretion impairment [40]. Therefore, it seems that the
inhibition of JNK phosphorylation plays an important role
in the platelet activation process.
The most noteworthy finding from the present study was
that cAMP production was elevated by CE6 treatment in
resting or ADP-activated platelets. P2Y12 receptor is capable
of inhibiting AC, thereby promoting platelet aggregation
[2]. Additionally, ADP suppresses intracellular cAMP levels
increased by constitutive activation of AC in intact platelets
[8]. Srinivasan et al. also reported that adenosine-based
P2Y12 (coupled to Gs) antagonists inhibit platelet aggrega-
tion, but adenosine-based P2Y1 (coupled to Gq)a n t a g o n i s t s
do not [8]. As such, considerable evidence has accumulated
supporting the theory that cAMP has a broad inhibitory
e ff e c to np l a t e l e ta c t i v a t i o n[ 24, 41]. With this knowledge, we
tested our hypothesis that CE6 would raise cAMP levels in
the rat platelets. As expected, CE6 markedly elevated cAMP
concentrations compared to forskolin, suggesting that the
inhibitory effect of CE6 on platelet activation is mediated
by cAMP. Moreover, the synergistic effect we observed with
the AC activator but not the PDE inhibitor indicates that
the elevation of cAMP production by CE6 is not due to
the inhibition of cAMP degradation through PDE activity
suppression.
It is well known that the target of cAMP is PKA, which
is composed of a regulatory subunit dimer and two catalytic
subunits [1, 6]. Indeed, treatment with CE6 at concentrations
that inhibited platelet aggregation increased the expression
of the active PKA catalytic subunit in the present study. Our
finding indicated that activation of the cAMP-PKA pathway
is responsible for the inhibition of platelet aggregation by
CE6. Unexpectedly, fibrinogen binding to integrin 𝗼IIb𝗽3
was much more affected by CE6 treatment compared to
intracellular cAMP levels. Several previous studies have
reported that inhibition of AC or ADP receptors does not
induceplateletaggregation[32,42].Thus,thecAMPpathway
elicited by CE6 might be of potentiating effect rather than
direct effect on integrin signaling.
The inhibition of integrin activation is of great interest
for the development of antiplatelet drugs. As a consequence
of active integrin conformation, outside-in signaling is a
major driving force for complete platelet aggregation [43].
Reversiblecellaggregationiseventuallyundergoingstabiliza-
tion, followed by outside-in signaling of fibrinogen. Several
lines of research have demonstrated that platelet aggregates
arecompletelyorpartiallydisassembledinADP-orcollagen-
stimulated platelets through either blocking of the P2Y12
receptor or suppression of PI3K [8, 44]. Based on these
findings and our data, we propose that ADP-activated PI3K
plays an important role in integrin activation, likely via G𝑖-
coupled signaling.
Alternatively,itwaspreviouslyshownthatPKCactivation
is inhibited by either blocking the P2Y12 receptor or inhibit-
ing PI3K activity [45]. These findings suggest that PKC holds
apivotalroleinthePI3K-Aktsignalingpathway.Asdiscussed
previously, the inhibition of PKC activity likely influenced
the negative effects of CE6 on platelet activation. During
the late stage of integrin activation, the ADP-P2Y12 receptor
helps regulate thrombus stabilization through the activation
of PI3K and Akt, which inhibits cAMP production [44]. Kim
et al. also reported that cAMP downregulates the activity
of Akt in COS cell by interfering PtdIns-3,4,5-P3 formation
[46], demonstrating the essential role of ADP in activation
of the Akt pathway [4]. Results from our study suggest that
the suppression of fibrinogen binding to 𝗼IIb𝗽3 by CE6 is
mediated by decreased activation of PI3K and Akt.10 Evidence-Based Complementary and Alternative Medicine
5. Conclusion
As summarized in Figure 10,w ed e m o n s t r a t e dt h a tC E 6
inhibited ADP-induced platelet aggregation, increases of
[Ca
2+]𝑖, TXA2 production, and dense granule secretion (i.e.,
ATP and serotonin release) in a concentration-dependent
m a n n e r .Th ep h o s p h o r y l a t i o no ft h et h r e eM A P K s( E R K 1 / 2 ,
p38-MAPK, and JNK) was also markedly inhibited by CE6
treatment. While the PI3K-Akt pathway was suppressed by
CE6, the cAMP-PKA pathway was activated. Based on our
data,weproposethatCE6actsthroughthecAMP-PKApath-
way to attenuate the expression and activity of intracellular
signaling molecules and suppress the activation of integrin
𝗼IIb𝗽3 activated by PI3K-Akt signaling, thereby preventing
the aggregation of ADP-stimulated platelets. The develop-
ment of innovative antiplatelet drugs has been focused on
the inhibition of ADP and TXA2 signaling [37]. Thus, CE6
could be developed as a therapeutic agent for preventing
thrombosis and ischemia.
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